This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Showalter SL , Rosato EL , Anne PR , Scott W , Mitchell E , Berger AC
Does Diabetes Mellitus Influence Pathologic Complete Response and Tumor Downstaging After Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Cancer? A Two-Institution Report
Journal of Surgical Oncology. 2010 Jan;101(1) :43-46
AbstractBackground: Esophageal carcinoma is an aggressive disease that is often treated with neoadjuvant therapy followed by surgical resection. Diabetes mellitus (DM) has been associated with reduced efficacy of chemoradiation (CRT) in other gastrointestinal cancers. The goal of this study was to determine if DM affects response to neoadjuvant CRT in the management of gastroesophageal carcinoma. Methods: We retrospectively reviewed the esophageal cancer patient databases and subsequently analyzed those patients who received neoadjuvant CRT followed by surgical resection at two institutions, Thomas Jefferson University (TJUH) and Fox Chase Cancer Center (FCCC). Comparative analyses of rates of pathologic complete response rate (pCR) and pathologic downstaging in DM patients versus non-DM patients was performed. Results: Two hundred sixty patients were included in the study; 36 patients had DM and 224 were non-diabetics. The average age of the patients was 61 years (range 24-84 years). The overall pCR was 26%. The pCR rate was 19% and 27% for patients with DM and without DM, respectively (P = 0.31). Pathologic downstaging occurred in 39% of study patients, including of 33% of DM patients and 40% of non-DM patients (P = 0.42). Conclusions: Although the Current analysis does not demonstrate a significant reduction in pCR rates or pathologic downstaging in patients with DM, the observed trend suggests that a potential difference may be observed with a larger patient population. Further studies are warranted to evaluate the influence of DM on the effectiveness of neoadjuvant CRT in esophageal cancer. J. Surg. Oncol. 2010;101:43-46 (C) 2009 Wiley-Liss, Inc.
NotesShowalter, Shayna L. Rosato, Ernest L. Anne, P. Rani Scott, Walter Mitchell, Edith Berger, Adam C. 29 Wiley-liss; div john wiley & sons inc, 111 river st, hoboken, nj 07030 usa 541vf